The platform is based on AI algorithms and allows scientists to create optimized formulas based on meta-analysis of peer-reviewed articles. NB-AIR, initially targeted for cell therapy developers, provides peer-tested compounds and formula recommendations based on cell type and critical quality attributes. The AI-guided formulations will improve performance of cell therapy and shorten the development time of the therapies, according to the firm.

The use of in vitro cell culture media has a well-documented effect on cell quality and therapeutic efficacy. Previously, researchers had to rely on suppliers who sell proprietary media formulation with little ability to modify the media for their specific needs.

"We are democratizing formulations enabling scientists to tap into the collective knowledge of their peers, become experts quickly and own their media formulation." said David Sheehan, founder, president, and chief executive officer of Nucleus Biologics.

Cognate, Nucleus Biologics partner on cell, gene therapy media
Contract development and manufacturing organization Cognate BioServices and Nucleus Biologics have partnered to provide custom and commercial medias and...